Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing Consortium aimed at pioneering new advances in how medicines are produced.

That's one of the key reasons Eli Lilly hasn't performed as well in recent months. Since many of its prospects are tied to its portfolio of drugs addressing obesity,, some investors might be ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...

Eli Lilly is experiencing explosive growth ... alone is growing at a much more accelerated rate than Lilly's business as a whole. One of the primary drivers for Verzenio's performance is an ...